Treatment Options in Metastatic Renal Carcinoma: An Embarrassment of Riches
- 1 January 2006
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (1) , 1-3
- https://doi.org/10.1200/jco.2005.03.7234
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Tyrosine Kinases as Targets for Cancer TherapyNew England Journal of Medicine, 2005
- Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)Journal of Clinical Oncology, 2005
- Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trialJournal of Clinical Oncology, 2005
- Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)Journal of Clinical Oncology, 2005
- Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trialJournal of Clinical Oncology, 2005
- Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)Journal of Clinical Oncology, 2005
- AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)Journal of Clinical Oncology, 2005
- Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003